Delivery Order SPE2DR25D1104-SPE2DR26FK070
- Not listed
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging) valued at $21,040.94, with an ultimate completion date of June 30, 2025. This non-set-aside award represents a competitive procurement supporting the agency's pharmaceutical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $6,147.19 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 8, 2025, with completion scheduled for August 11, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical supply delivery to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $45,395.82 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on September 24, 2025, with completion scheduled for September 25, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing for pharmaceutical delivery to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $4,265.94 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with completion targeted for August 27, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under an existing contract vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement,...
- The Defense Logistics Agency awarded a $19,152.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging). The contract was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a $3,111.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count) on July 14, 2025, with completion due July 15, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order valued at $10,040.64 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-set-aside competitive award was issued on September 26, 2025, with an ultimate completion date of September 29, 2025. The contract is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit of use packaging) under a firm fixed-price contract valued at $60,356.04, with completion scheduled for September 17, 2025. This non-set-aside competitive award leverages AmerisourceBergen's position as a major pharmaceutical distributor and represents a continuation of the company's extensive support to federal medical...
- The Defense Logistics Agency awarded a $12,446.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement fulfilling federal medical supply requirements. The award was made to AmerisourceBergen's Corporate Office division, located in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a delivery order valued at $7,181.62 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a firm fixed price and September 23, 2025 completion date. This is a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. The award was issued to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters, which serves as a critical...
- SPE2DR25D1104Indefinite Delivery Contract
- SPE2DR25D1104-SPE2DR26FK070Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $6,004.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on October 20, 2025, with completion scheduled for October 21, 2025. This non-set-aside award represents a standard pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order operates under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vendor contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The underlying IDC reflects the company's demonstrated capability to meet federal procurement requirements through open competition and positions it as a key supplier for the DLA's pharmaceutical support mission.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 10/20/25 |